HALO-BIO RNAI THERAPEUTICS

Welcome to Halo-Bio RNAi Therapeutics Inc., an early stage company utilizing the novel 'Multivalent RNAi Platform' to develop multi-gene targeting products for the treatment of disease. NOVEL RNAi TECHNOLOGIES The Multivalent RNA molecule (MV-RNA) represent a new RNAi trigger for the treatment of disease. The non-canonical structure utilizes the same RISC pathway as siRNA, but expands gene targeting, eliminates sense-strand off-target effects, and introduces the first 'junction containing' stru... cture to RNAi. With an exlusive IP position and novel technical characteristics, Halo-Bio is working to release Multivalent RNAi based products that utilize MV-RNA's unique capabilities. EXPERTS IN SINGLE-MOLECULE, MULTI-GENE SUPPRESSION Multivalent RNA is an elegant single-molecule with advantages in molecular characterization, product cost, and IP ROI. While MV-RNA are more complicated than siRNA given their multivalency, Halo has the expertise and tools to apply MV-RNA to just about any series of target genes. SOPHISTICATED DESIGN, POWERFUL API, ELEGANT DELIVERY Halo has spent years developing design support in the form a a powerful computational array called, "Multivalent RNAi Cloud". This enterprise system ensures that products using MV-RNA as the Active Pharmaceutical Ingredient are based on the best possible designs for efficacy and specificity. MV-RNA share the same mechanism of action with canonical siRNA, but they are simply different otherwise. Knowing how to take advantage of this difference is central to Halo being able to provide novel product design, function, and even a new form of RNAi delivery.More